Nano Dimension to Review its Options Relative to Stratasys
Comments on Stratasys’ Response to Its All-Cash Offer Expresses Disappointment in Stratasys’ Refusal to Engage Waltham, Mass., March 23, 2023 ...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
23-03-2023, 13:00
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
22-03-2023, 21:00
Five Star Bancorp Names New Board Chair & Vice Chair
RANCHO CORDOVA, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) and its wholly owned subsidiary, Five Star Bank, (“Five Star”...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
22-03-2023, 17:00
CytomX Therapeutics to Report Fourth Quarter and Full Year
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
22-03-2023, 13:00
Nano Dimension’s Chairman and CEO on The Falsity of
An Explanation on Why The Meeting and Therefore The Vote Were Invalid...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
21-03-2023, 21:00
Feutune Light Acquisition Corporation Announces Intention
Metuchen, New Jersey, March 21, 2023 (GLOBE NEWSWIRE) -- Feutune Light Acquisition Corporation (NASDAQ: FLFV) (the “Company”), a blank check company...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
21-03-2023, 20:00
InterDigital to Present at the Sidoti Small-Cap Virtual
WILMINGTON, Del., March 21, 2023 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile and video technology research and development company,...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
21-03-2023, 04:00
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
20-03-2023, 05:00
BioNTech and OncoC4 Announce Strategic Collaboration to
BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392BioNTech and...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
18-03-2023, 00:00
Celyad Oncology to announce full year 2022 financial
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...
&#x/templates/trangcongnghe_en/dleimages/no_icon.gif;
17-03-2023, 18:00
VERB to Host Fourth Quarter and Full Year 2022 Earnings
NEWPORT BEACH, Calif. and SALT LAKE CITY, March 17, 2023 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (NASDAQ: VERB) (“VERB” or the “Company”), the...
